AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22867295 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling (unstructured/nondirective)
Number of subjects: 302
Study 22867295 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling (unstructured/directive)
Number of subjects: 302
Study 22867295 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling (structured/nondirective)
Number of subjects: 302
Study 22867295 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling (structured/directive)
Number of subjects: 302
Study 22867295 — intervention group
Group type: COMPARATOR
Intervention: No call/control group
Number of subjects: 302
Study 21235696 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial combination therapy with sitagliptin 100 mg q.d. and pioglitazone 30 mg q.d.
Number of subjects: 520
Study 21235696 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone 30 mg q.d. monotherapy
Number of subjects: 520
Study 21235696 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial combination therapy with sitagliptin and pioglitazone
Number of subjects: 520
Study 21235696 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone monotherapy
Number of subjects: 520
Study 19491283 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (400 mg/m² on week 1 followed by 250 mg/m² weekly)
Number of subjects: 55
Study 19491283 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 55
Study 17218374 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone 15 mg
Number of subjects: 60
Study 17218374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 16676098 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate 100 mg/day for one month
Number of subjects: 14
Study 16676098 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 14
Study 14575232 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg once daily
Number of subjects: 0
Study 14575232 — intervention group
Group type: COMPARATOR
Intervention: Losartan 50 mg once daily
Number of subjects: 0
Study 10474149 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrophage colony stimulating factor (M‐CSF)
Number of subjects: 0
Study 7740012 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom training
Number of subjects: 0
Study 7740012 — intervention group
Group type: EXPERIMENTAL
Intervention: Television programming
Number of subjects: 0
Study 7740012 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of classroom and television delivery
Number of subjects: 0
Study 7740012 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 0
Study 7740012 — intervention group
Group type: COMPARATOR
Intervention: Attention control (Control)
Number of subjects: 0
Study 2405349 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam, 150 mg/kg/day intravenously
Number of subjects: 36
Study 2405349 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol, 100 mg/kg/day orally
Number of subjects: 36
Study 6993252 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (100 mg) plus Althiazide (60 mg)
Number of subjects: 22
Study 6993252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 29494294 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT + BR
Number of subjects: 30
Study 29494294 — intervention group
Group type: COMPARATOR
Intervention: SIT
Number of subjects: 30
Study 27392550 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivorship Care Plans (SCPs)
Number of subjects: 221
Study 27392550 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 221
Study 25343848 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention (MindBabyBody program)
Number of subjects: 52
Study 25343848 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 52
Study 25343848 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-randomised trial intervention
Number of subjects: 52
Study 23485845 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrust and nonthrust manipulation and exercise with myofascial therapy
Number of subjects: 50
Study 23485845 — intervention group
Group type: COMPARATOR
Intervention: Thrust and nonthrust manipulation and exercise without myofascial therapy
Number of subjects: 50
Study 20806430 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group (sulfasalazine 2400 mg/d with probiotic)
Number of subjects: 30
Study 20806430 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine group (sulfasalazine 2400 mg/d)
Number of subjects: 30
Study 18821688 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg from baseline through week 96, administered every 6 weeks after a loading dose
Number of subjects: 279
Study 18821688 — intervention group
Group type: COMPARATOR
Intervention: Placebo through week 24 and then infliximab 5 mg/kg from week 24 through week 96
Number of subjects: 279
Study 18821688 — intervention group
Group type: COMPARATOR
Intervention: Historical control cohort from OASIS database (no prior use of anti-TNF agents)
Number of subjects: 279
Study 15820274 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Number of subjects: 62
Study 12461760 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow release melatonin 6 mg
Number of subjects: 44
Study 12461760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 10337851 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT) with chromium picolinate supplementation (17.8 micromol chromium per day, 924 microg Cr/d)
Number of subjects: 32
Study 10337851 — intervention group
Group type: COMPARATOR
Intervention: Resistance training (RT) without chromium picolinate supplementation (placebo <0.1 microg Cr/d)
Number of subjects: 32
Study 8554944 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline (four doses of 10 mg over the preceding 3 days)
Number of subjects: 8
Study 8554944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1710660 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of gamma globulin (IVGG) plus aspirin
Number of subjects: 0
Study 1710660 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 0
Study 6939733 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-instructional programs in nutrition
Number of subjects: 83
Study 6939733 — intervention group
Group type: COMPARATOR
Intervention: Traditional lectures
Number of subjects: 83
Study 31131679 — intervention group
Group type: EXPERIMENTAL
Intervention: Active SBCM (treatment)
Number of subjects: 61
Study 31131679 — intervention group
Group type: COMPARATOR
Intervention: Passive referral (control)
Number of subjects: 61
Study 31131679 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 61
Study 28699628 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% sleep restriction with advanced wake-time
Number of subjects: 18
Study 25811951 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan-coated sutures
Number of subjects: 281
Study 25811951 — intervention group
Group type: COMPARATOR
Intervention: Control group (polyglactin 910 without triclosan)
Number of subjects: 281
Study 24001006 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous trial conflict
Number of subjects: 0
Study 24001006 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained intertrial effects in left parietal theta power
Number of subjects: 0
Study 24001006 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained intertrial effects in midcentral beta power
Number of subjects: 0
Study 24001006 — intervention group
Group type: EXPERIMENTAL
Intervention: Current trial conflict adaptation effect in midfrontal theta power
Number of subjects: 0
Study 24001006 — intervention group
Group type: EXPERIMENTAL
Intervention: Intertrial effects
Number of subjects: 0
Study 24001006 — intervention group
Group type: EXPERIMENTAL
Intervention: Conflict adaptation effects in midfrontal theta power and RTs
Number of subjects: 0
Study 21389923 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic right hemicolectomy with extracorporeal anastomosis (LAC)
Number of subjects: 45
Study 21389923 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic right hemicolectomy with intracorporeal anastomosis (TLC)
Number of subjects: 45
Study 19377437 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia with premedication
Number of subjects: 60
Study 19377437 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 60
Study 17362495 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate restoration with tapered, roughened-surface Southern implants, provisional screw-retained crowns placed within 4 hours of implant placement, and definitive crowns placed 8 weeks later
Number of subjects: 28
Study 17362495 — intervention group
Group type: COMPARATOR
Intervention: Conventional two-stage restoration with tapered, roughened-surface Southern implants, provisional screw-retained crowns placed after 26 weeks, and definitive crowns placed 8 weeks later
Number of subjects: 28
Study 15377561 — intervention group
Group type: EXPERIMENTAL
Intervention: Living in institutions
Number of subjects: 15403
Study 15377561 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual handicap
Number of subjects: 15403
Study 15377561 — intervention group
Group type: EXPERIMENTAL
Intervention: Blindness
Number of subjects: 15403
Study 15377561 — intervention group
Group type: EXPERIMENTAL
Intervention: Low vision
Number of subjects: 15403
Study 10770520 — intervention group
Group type: COMPARATOR
Intervention: Baclofen treatment
Number of subjects: 14
Study 10770520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 9315540 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (3 g intravenous infusion)
Number of subjects: 22
Study 9315540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 8348391 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg bid
Number of subjects: 6
Study 8348391 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 120 mg bid
Number of subjects: 6
Study 8348391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 3528989 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training programme
Number of subjects: 33
Study 3528989 — intervention group
Group type: COMPARATOR
Intervention: Information-contact condition
Number of subjects: 33
Study 3528989 — intervention group
Group type: COMPARATOR
Intervention: Self-registration group
Number of subjects: 33
Study 30923305 — intervention group
Group type: EXPERIMENTAL
Intervention: EVR/rTAC
Number of subjects: 0
Study 30923305 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC Elimination
Number of subjects: 0
Study 30923305 — intervention group
Group type: COMPARATOR
Intervention: TAC Control
Number of subjects: 0
Study 28801704 — intervention group
Group type: EXPERIMENTAL
Intervention: Anteromedial portal (AMP) technique
Number of subjects: 88
Study 28801704 — intervention group
Group type: COMPARATOR
Intervention: Transtibial (TT) technique
Number of subjects: 88
Study 28801704 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of femoral tunnel orientation
Number of subjects: 88
Study 26855045 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable calcium phosphate cement (Calcibon)
Number of subjects: 45
Study 26855045 — intervention group
Group type: EXPERIMENTAL
Intervention: Local bone autograft
Number of subjects: 45
Study 26855045 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliac crest autograft
Number of subjects: 45
Study 26855045 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study 23692637 — intervention group
Group type: EXPERIMENTAL
Intervention: MultiStem (400 million cells per patient)
Number of subjects: 0
Study 23692637 — intervention group
Group type: EXPERIMENTAL
Intervention: MultiStem (1200 million cells per patient)
Number of subjects: 0
Study 23692637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23692637 — intervention group
Group type: EXPERIMENTAL
Intervention: MultiStem
Number of subjects: 0
Study 22710954 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm labor group (group I)
Number of subjects: 120
Study 22710954 — intervention group
Group type: COMPARATOR
Intervention: Gestational age‐matched control pregnants (group II)
Number of subjects: 120
Study 22710954 — intervention group
Group type: COMPARATOR
Intervention: Pregnants with labor at term (group III)
Number of subjects: 120
Study 22710954 — intervention group
Group type: COMPARATOR
Intervention: Gestational age‐matched control pregnants (group IV)
Number of subjects: 120
Study 20106532 — intervention group
Group type: COMPARATOR
Intervention: Infant-directed video on
Number of subjects: 0
Study 20106532 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant-directed video off
Number of subjects: 0
Study 18760145 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 898
Study 18760145 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal pro-brain natriuretic peptide (NT-proBNP) at 6 months
Number of subjects: 898
Study 18760145 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 898
Study 18760145 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization to an early invasive strategy
Number of subjects: 898
Study 18760145 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent cTnI elevation
Number of subjects: 898
Study 18760145 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP level at 6 months
Number of subjects: 898
Study 15907416 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary treatment with estrogen (group 2)
Number of subjects: 30
Study 15907416 — intervention group
Group type: COMPARATOR
Intervention: No intracoronary treatment (group 1)
Number of subjects: 30
Study 12562411 — intervention group
Group type: EXPERIMENTAL
Intervention: Mainstream capnometry
Number of subjects: 240
Study 12562411 — intervention group
Group type: COMPARATOR
Intervention: Sidestream capnometry
Number of subjects: 240
Study 10832659 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated circuit
Number of subjects: 20
Study 10832659 — intervention group
Group type: COMPARATOR
Intervention: Uncoated circuit
Number of subjects: 20
Study 8807689 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational multifamily groups
Number of subjects: 68
Study 8807689 — intervention group
Group type: COMPARATOR
Intervention: Episodic crisis family intervention
Number of subjects: 68
Study 8807689 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment conditions
Number of subjects: 68
Study 14621851 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyclonal antilymphocyte globulins (ALG) for 7 days (n = 28)
Number of subjects: 55
Study 14621851 — intervention group
Group type: COMPARATOR
Intervention: Monoclonal T‐cell‐specific antibodies (OKT3) for 7 days (n = 27)
Number of subjects: 55
Study 14621851 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ALG and OKT3)
Number of subjects: 55
Study 3894437 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine hydrochloride
Number of subjects: 10
Study 31542245 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (improved physical activity and healthy dietary intakes)
Number of subjects: 560
Study 31542245 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 560
Study 31542245 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 560
Study 31574106 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal-assisted therapy (AAT)
Number of subjects: 10
Study 31574106 — intervention group
Group type: COMPARATOR
Intervention: Control sessions (conventional therapy)
Number of subjects: 10
Study 27107979 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional strength training
Number of subjects: 93
Study 27107979 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement performance therapy
Number of subjects: 93
Study 27107979 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 93
Study 25348544 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 implant in the midline (group 1)
Number of subjects: 86
Study 25348544 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 implants in the canine areas (group 2)
Number of subjects: 86
Study 25348544 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 86
Study 23183433 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for tuberculosis
Number of subjects: 144
Study 22147963 — intervention group
Group type: EXPERIMENTAL
Intervention: FibroSURE (FS)
Number of subjects: 2060
Study 22147963 — intervention group
Group type: EXPERIMENTAL
Intervention: FibroScan (TE)
Number of subjects: 2060
Study 22147963 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined FibroSURE/TE
Number of subjects: 2060
Study 22147963 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined FS/TE in Asians
Number of subjects: 2060
Study 22147963 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline FS
Number of subjects: 2060
Study 22147963 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline TE
Number of subjects: 2060
Study 22147963 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall FS/TE agreement for F2-4
Number of subjects: 2060
Study 19741604 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0493
Number of subjects: 0
Study 19741604 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg sibutramine
Number of subjects: 0
Study 19741604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16289651 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 116
Study 16289651 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 116
Study 16289651 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 116
Study 16289651 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine-artesunate
Number of subjects: 116
Study 15172654 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. ibutilide treatment, up to 2 mg
Number of subjects: 87
Study 15172654 — intervention group
Group type: COMPARATOR
Intervention: Transoesophageal atrial pacing (ATP)
Number of subjects: 87
Study 11717611 — intervention group
Group type: EXPERIMENTAL
Intervention: Right Atrial Appendage Pacing (RAAP)
Number of subjects: 46
Study 11717611 — intervention group
Group type: EXPERIMENTAL
Intervention: Interatrial Septum Pacing (IASP)
Number of subjects: 46
Study 9142515 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal retropharyngeal lymph nodes (RLN) size measurement
Number of subjects: 44
Study 9142515 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 subjects)
Number of subjects: 44
Study 9142515 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical association analysis
Number of subjects: 44
Study 9142515 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of nasopharyngeal walls involvement and maximum diameter of the tumor
Number of subjects: 44
Study 8737553 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal bupivacaine (0.5ml/kg body weight of 0.25% solution)
Number of subjects: 85
Study 8737553 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine (4 micrograms/ml, volume of 0.5 ml/kg body weight in normal saline)
Number of subjects: 85
Study 3297570 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of metronidazole (1.5 g) and ampicillin (3.0 g)
Number of subjects: 294
Study 3297570 — intervention group
Group type: COMPARATOR
Intervention: Multiple doses of ampicillin (1 g X 3) and metronidazole (0.5 g X 3)
Number of subjects: 294
Study 3297570 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of metronidazole and ampicillin
Number of subjects: 294
Study 1692390 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG 7S
Number of subjects: 64
Study 1692390 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG 5S
Number of subjects: 64
Study 29952805 — intervention group
Group type: EXPERIMENTAL
Intervention: Distortion product OAE (DPOAE) with controlled reflection-source contribution
Number of subjects: 212
Study 29952805 — intervention group
Group type: EXPERIMENTAL
Intervention: Distortion-source DPOAEs
Number of subjects: 212
Study 29952805 — intervention group
Group type: COMPARATOR
Intervention: Reflection-source AM-SFOAEs
Number of subjects: 212
Study 29952805 — intervention group
Group type: COMPARATOR
Intervention: DPOAE conditions
Number of subjects: 212
Study 28923291 — intervention group
Group type: EXPERIMENTAL
Intervention: Omarigliptin 25 mg once weekly
Number of subjects: 203
Study 28923291 — intervention group
Group type: COMPARATOR
Intervention: Placebo once weekly
Number of subjects: 203
Study 28923291 — intervention group
Group type: COMPARATOR
Intervention: Prohibited medication (metformin)
Number of subjects: 203
Study 25755093 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast Skipping (NB) for Eaters
Number of subjects: 18
Study 25755093 — intervention group
Group type: COMPARATOR
Intervention: Breakfast Eating (B) for Skippers
Number of subjects: 18
Study 23824699 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 205
Study 23824699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study 21565651 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based decision aid
Number of subjects: 264
Study 19593171 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (FMZ) 2 mg incremental bolus for 20 minutes for 2 consecutive days and Gabapentin (GBP) up to 1200 mg nightly for 39 days
Number of subjects: 60
Study 19593171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19593171 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (FMZ) and Gabapentin (GBP)
Number of subjects: 60
Study 17203620 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for depression in primary care
Number of subjects: 0
Study 17203620 — intervention group
Group type: EXPERIMENTAL
Intervention: Management strategies (training staff, consultation-liaison, collaborative care, replacement/referral)
Number of subjects: 0
Study 17203620 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants prescribed at effective doses
Number of subjects: 0